{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:14Z","timestamp":1790717114458,"version":"4.1.0"},"reference-count":172,"publisher":"Journal of Neurosurgery Publishing Group (JNSPG)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["FOC"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:p>Glioblastoma is both the most common and most lethal primary CNS malignancy in adults, accounting for 45.6% of all malignant CNS tumors, with a 5-year survival rate of only 5.0%, despite the utilization of multimodal therapy including resection, chemotherapy, and radiation. Currently available treatment options for glioblastoma often remain limited, offering brief periods of improved survival, but with substantial side effects. As such, improvements in current treatment strategies or, more likely, the implementation of novel strategies altogether are warranted. In this topic review, the authors provide a comprehensive review on the potential of alternating electric fields (AEFs) in the treatment of glioblastoma. Alternating electric fields\u2014also known as tumor-treating fields (TTFs)\u2014represent an entirely original therapeutic modality with preliminary studies suggesting comparable, and at times improved, efficacy to standard chemotherapeutic agents in the treatment of recurrent glioblastoma. A recent multicenter, Phase III, randomized clinical trial comparing NovoTTF-100A monotherapy to physician's best choice chemotherapy in patients with recurrent glioblastoma revealed that AEFs have similar efficacy to standard chemotherapeutic agents with a more favorable side-effects profile and improved quality of life. In particular, AEFs were shown to have limited systemic adverse effects, with the most common side effect being contact dermatitis on the scalp at the sites of transducer placement. This study prompted FDA approval of the NovoTTF-100A system in April 2011 as a standalone therapy for treatment of recurrent glioblastoma refractory to surgical and radiation treatment. In addition to discussing the available clinical evidence regarding the utilization of AEFs in glioblastoma, this article provides essential information regarding the supposed therapeutic mechanism as well as modes of potential tumor resistance to such novel therapy, delineating future perspectives regarding basic science research on the issue.<\/jats:p>","DOI":"10.3171\/2015.1.focus14742","type":"journal-article","created":{"date-parts":[[2015,3,2]],"date-time":"2015-03-02T03:36:59Z","timestamp":1425267419000},"page":"E14","source":"Crossref","is-referenced-by-count":33,"title":["The effects of alternating electric fields in glioblastoma: current evidence on therapeutic mechanisms and clinical outcomes"],"prefix":"10.3171","volume":"38","author":[{"given":"Azeem A.","family":"Rehman","sequence":"first","affiliation":[{"name":"University of Illinois College of Medicine at Peoria, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B.","family":"Elmore","sequence":"additional","affiliation":[{"name":"University of Illinois College of Medicine at Peoria, Illinois; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias A.","family":"Mattei","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain & Spine Center, Invision Health, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1754","reference":[{"key":"b1-focus14742","series-title":"Stem Cell Rev","first-page":"585","article-title":"The influence of electric fields on hippocampal neural progenitor cells","volume":"6","author":"Ariza","year":"2010"},{"key":"b2-focus14742","series-title":"J Korean Med Sci","first-page":"980","article-title":"Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea","volume":"29","author":"Bae","year":"2014"},{"issue":"124","key":"b3-focus14742","series-title":"Clin Orthop Relat Res","first-page":"128","article-title":"A non-operative salvage of surgically-resistant pseudarthroses and non-unions by pulsing electromagnetic fields. A preliminary report","author":"Bassett","year":"1977"},{"key":"b4-focus14742","series-title":"Nature","first-page":"608","article-title":"Influencing intramolecular motion with an alternating electric field","volume":"406","author":"Bermudez","year":"2000"},{"key":"b5-focus14742","series-title":"J Neuropathol Exp Neurol","first-page":"201","article-title":"Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas","volume":"40","author":"Bigner","year":"1981"},{"key":"b6-focus14742","series-title":"Lancet","first-page":"1008","article-title":"Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas","volume":"345","author":"Brem","year":"1995"},{"key":"b7-focus14742","series-title":"Cancer","first-page":"1617","article-title":"Patient age, histologic features, and length of survival in patients with glioblastoma multiforme","volume":"59","author":"Burger","year":"1987"},{"key":"b8-focus14742","series-title":"J Int Med Res","first-page":"85","article-title":"Growth inhibition of malignant melanoma by intermediate frequency alternating electric fields, and the underlying mechanisms","volume":"40","author":"Chen","year":"2012"},{"key":"b9-focus14742","series-title":"Cancer","first-page":"2163","article-title":"Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries","volume":"118","author":"Darefsky","year":"2012"},{"key":"b10-focus14742","series-title":"Br J Neurosurg","first-page":"459","article-title":"The sequential use of carmustine wafers (Gliadel\u00ae) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review","volume":"25","author":"Dixit","year":"2011"},{"key":"b11-focus14742","series-title":"Case Rep Neurol","first-page":"109","article-title":"Resolution of cystic enhancement to add-on tumor treating electric fields for recurrent glioblastoma after incomplete response to bevacizumab","volume":"6","author":"Elzinga","year":"2014"},{"key":"b12-focus14742","series-title":"Cell Death Differ","first-page":"1238","article-title":"Chemotherapy resistance of glioblastoma stem cells","volume":"13","author":"Eramo","year":"2006"},{"issue":"Suppl 3","key":"b13-focus14742","series-title":"Neuro Oncol","first-page":"iii76","article-title":"MR-008. Phase III trial of tumor treating fields (TTFields) together with temozolomide (TMZ) compared to temozolomide alone in patients with newly diagnosed glioblastoma (GBM)","volume":"15","author":"Farber","year":"2013"},{"key":"b14-focus14742","series-title":"Expert Rev Neurother","first-page":"895","article-title":"NovoTTF-100A: a new treatment modality for recurrent glioblastoma","volume":"12","author":"Fonkem","year":"2012"},{"key":"b15-focus14742","series-title":"J Clin Oncol","first-page":"4733","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009"},{"key":"b16-focus14742","series-title":"Proc Natl Acad Sci U S A","first-page":"14142","article-title":"Electronic detection of DNA by its intrinsic molecular charge","volume":"99","author":"Fritz","year":"2002"},{"key":"b17-focus14742","series-title":"Electrophoresis","first-page":"1973","article-title":"Particle separation by dielectrophoresis","volume":"23","author":"Gascoyne","year":"2002"},{"issue":"Suppl 3","key":"b18-focus14742","series-title":"Neuro Oncol","first-page":"iii43","article-title":"ET-029. Overcoming cell size escape from tumor treating fields using a varying frequency treatment paradigm in-vitro","volume":"15","author":"Giladi","year":"2013"},{"issue":"Suppl 3","key":"b19-focus14742","series-title":"Neuro Oncol","first-page":"iii43","article-title":"ET-028. Alternating electric fields (TT-Fields) inhibit DNA damage repair response in cancer cell lines","volume":"15","author":"Giladi","year":"2013"},{"issue":"Suppl 3","key":"b20-focus14742","series-title":"Neuro Oncol","first-page":"iii86","article-title":"MP-005. Meta-analysis of cancer cell line genomes based on their response to alternating electric fields (TTFields)","volume":"15","author":"Giladi","year":"2013"},{"key":"b21-focus14742","series-title":"Angew Chem Int Ed Engl","first-page":"3022","article-title":"Why are proteins charged? Networks of charge-charge interactions in proteins measured by charge ladders and capillary electrophoresis","volume":"45","author":"Gitlin","year":"2006"},{"key":"b22-focus14742","series-title":"Ann Biomed Eng","first-page":"1759","article-title":"Electrically mediated neuronal guidance with applied alternating current electric fields","volume":"39","author":"Graves","year":"2011"},{"key":"b23-focus14742","series-title":"Oncology","first-page":"27","article-title":"Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis","volume":"79","author":"Hapani","year":"2010"},{"key":"b24-focus14742","series-title":"Biomed Microdevices","first-page":"657","article-title":"Electrical field manipulation of cancer cell behavior monitored by whole cell biosensing device","volume":"15","author":"Hondroulis","year":"2013"},{"key":"b25-focus14742","series-title":"J Neurooncol","first-page":"359","article-title":"Glioblastoma survival in the United States before and during the temozolomide era","volume":"107","author":"Johnson","year":"2012"},{"issue":"Suppl 3","key":"b26-focus14742","series-title":"Neuro Oncol","first-page":"iii114","article-title":"NO-065. Tumor treating fields (TTFields) in recurrent GBM. An updated subgroup analysis of the phase III data","volume":"15","author":"Kanner","year":"2013"},{"key":"b27-focus14742","series-title":"Semin Oncol 41 Suppl","first-page":"S25","article-title":"Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A\u2122 system versus best physician's choice chemotherapy","volume":"6","author":"Kanner","year":"2014"},{"key":"b28-focus14742","series-title":"Proc Natl Acad Sci U S A","first-page":"10152","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","volume":"104","author":"Kirson","year":"2007"},{"key":"b29-focus14742","series-title":"Cancer Res","first-page":"3288","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004"},{"key":"b30-focus14742","series-title":"BMC Med Phys","first-page":"1","article-title":"Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)","volume":"9","author":"Kirson","year":"2009"},{"issue":"Suppl 4","key":"b31-focus14742","series-title":"Neuro Oncol","first-page":"iv48","article-title":"NO-54. Modeling tumor growth kinetics and its implications for TTFields treatment planning","volume":"12","author":"Kirson","year":"2010"},{"key":"b32-focus14742","series-title":"J BUON","first-page":"547","article-title":"Temozolomide-related infections: review of the literature","volume":"16","author":"Kizilarslanoglu","year":"2011"},{"key":"b33-focus14742","series-title":"J Clin Oncol","first-page":"740","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009"},{"key":"b34-focus14742","series-title":"Cancer","first-page":"649","article-title":"Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group","volume":"47","author":"Kristiansen","year":"1981"},{"issue":"Suppl 4","key":"b35-focus14742","series-title":"Semin Oncol","first-page":"S1","article-title":"Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma","volume":"41","author":"Lacouture","year":"2014"},{"key":"b36-focus14742","series-title":"J Neurosurg","first-page":"467","article-title":"Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project","volume":"99","author":"Laws","year":"2003"},{"issue":"Suppl 3","key":"b37-focus14742","series-title":"Neuro Oncol","first-page":"iii66","article-title":"IR-022. Disruption of cell division within anaphase by tumor treating electric fields (TTFields) leads to immunogenic cell death","volume":"15","author":"Lee","year":"2013"},{"key":"b38-focus14742","series-title":"Acta Neuropathol","first-page":"97","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007"},{"key":"b39-focus14742","series-title":"Biotechnol Prog","first-page":"664","article-title":"Alternating current electric field effects on neural stem cell viability and differentiation","volume":"26","author":"Matos","year":"2010"},{"key":"b40-focus14742","series-title":"J Neurosurg","first-page":"583","article-title":"Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme","volume":"110","author":"McGirt","year":"2009"},{"key":"b41-focus14742","series-title":"Annu Rev Cell Dev Biol","first-page":"193","article-title":"Chromosome-microtubule interactions during mitosis","volume":"18","author":"McIntosh","year":"2002"},{"key":"b42-focus14742","series-title":"Phys Med Biol","first-page":"4137","article-title":"Predicting the electric field distribution in the brain for the treatment of glioblastoma","volume":"59","author":"Miranda","year":"2014"},{"key":"b43-focus14742","series-title":"Semin Oncol 41 Suppl","first-page":"S4","article-title":"Clinical practice experience with NovoTTF-100A\u2122 system for glioblastoma: the Patient Registry Dataset (PRiDe)","volume":"6","author":"Mrugala","year":"2014"},{"issue":"Suppl 2","key":"b44-focus14742","series-title":"Neuro Oncol","first-page":"ii101","article-title":"P17.60. Novo-TTF 100A system used successfully in a patient with a ventriculo-peritoneal shunt","volume":"16","author":"Mrugala","year":"2014"},{"key":"b45-focus14742","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Central nervous system cancers. Version 2.2014","author":"National Comprehensive Cancer Network","year":"2014"},{"key":"b46-focus14742","series-title":"J Biomed Mater Res A","first-page":"2554","article-title":"Electric field stimulation through a biodegradable polypyrrole-co-polycaprolactone substrate enhances neural cell growth","volume":"102","author":"Nguyen","year":"2014"},{"key":"b47-focus14742","series-title":"Neurology","first-page":"779","article-title":"Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence","volume":"70","author":"Norden","year":"2008"},{"key":"b48-focus14742","series-title":"Biochem Biophys Res Commun","first-page":"351","article-title":"Nanosecond pulsed electric fields cause melanomas to self-destruct","volume":"343","author":"Nuccitelli","year":"2006"},{"key":"b49-focus14742","series-title":"Neuro Oncol","first-page":"iv1","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011","volume":"16 Suppl 4","author":"Ostrom","year":"2014"},{"key":"b50-focus14742","series-title":"J Neurosci Res","first-page":"1522","article-title":"Neuronal responses to an asymmetrical alternating current field can mimic those produced by an imposed direct current field in vitro","volume":"90","author":"Pan","year":"2012"},{"key":"b51-focus14742","series-title":"J Cell Physiol","first-page":"602","article-title":"5'-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells","volume":"228","author":"Quezada","year":"2013"},{"key":"b52-focus14742","series-title":"J Neurosci","first-page":"3030","article-title":"Spike timing amplifies the effect of electric fields on neurons: implications for endogenous field effects","volume":"27","author":"Radman","year":"2007"},{"issue":"Suppl 4","key":"b53-focus14742","series-title":"Neuro Oncol","first-page":"iv48","article-title":"NO-55. Subgroup and quality of life analyses of the phase III clinical trial of NovoTTF-100A versus best standard chemotherapy for recurrent glioblastoma","volume":"12","author":"Ram","year":"2010"},{"issue":"Suppl 3","key":"b54-focus14742","series-title":"Neuro Oncol","first-page":"iii52","article-title":"NO-50. Comparing the effect of NovoTTF to bevacizumab in recurrent GBM: a post-hoc sub-analysis of the phase III trial data","volume":"13","author":"Ram","year":"2011"},{"key":"b55-focus14742","series-title":"Front Hum Neurosci","first-page":"687","article-title":"Effects of weak transcranial alternating current stimulation on brain activity\u2014 a review of known mechanisms from animal studies","volume":"7","author":"Reato","year":"2013"},{"key":"b56-focus14742","series-title":"World J Surg Oncol","first-page":"220","article-title":"Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields","volume":"10","author":"Rulseh","year":"2012"},{"key":"b57-focus14742","series-title":"J Neurosurg Sci","first-page":"1","article-title":"Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis","volume":"55","author":"Salvati","year":"2011"},{"key":"b58-focus14742","series-title":"Exp Cell Res","first-page":"380","article-title":"Redox control of angiogenic factors and CD31-positive vessel-like structures in mouse embryonic stem cells after direct current electrical field stimulation","volume":"304","author":"Sauer","year":"2005"},{"key":"b59-focus14742","series-title":"Oncogene","first-page":"1385","article-title":"Comparative molecular genetic profiles of anaplastic astrocytomas\/glioblastomas multiforme and their subsequent recurrences","volume":"18","author":"Saxena","year":"1999"},{"issue":"Suppl 3","key":"b60-focus14742","series-title":"Neuro Oncol","first-page":"iii99","article-title":"NO-006. Radiographic response of an incidental meningioma in a patient with glioblastoma on NovoTTF therapy","volume":"15","author":"Schaff","year":"2013"},{"key":"b61-focus14742","series-title":"CA Cancer J Clin","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014"},{"key":"b62-focus14742","series-title":"J Cell Biochem","first-page":"404","article-title":"Prospects on clinical applications of electrical stimulation for nerve regeneration","volume":"51","author":"Sisken","year":"1993"},{"key":"b63-focus14742","series-title":"Lancet Oncol","first-page":"459","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009"},{"key":"b64-focus14742","series-title":"N Engl J Med","first-page":"987","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005"},{"key":"b65-focus14742","series-title":"Eur J Cancer","first-page":"2192","article-title":"NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012"},{"key":"b66-focus14742","series-title":"BioDrugs","first-page":"159","article-title":"Bevacizumab-induced hypertension: pathogenesis and management","volume":"25","author":"Syrigos","year":"2011"},{"key":"b67-focus14742","series-title":"Bioelectrochemistry","first-page":"257","article-title":"Electroporation and alternating current cause membrane permeation of photodynamic cytotoxins yielding necrosis and apoptosis of cancer cells","volume":"79","author":"Traitcheva","year":"2010"},{"key":"b68-focus14742","series-title":"Physiol Meas","first-page":"13","article-title":"Computational modelling of blood-flow-induced changes in blood electrical conductivity and its contribution to the impedance cardiogram","volume":"31","author":"Trakic","year":"2010"},{"key":"b69-focus14742","series-title":"J Rheumatol","first-page":"1903","article-title":"The effect of pulsed electromagnetic fields in the treatment of osteoarthritis of the knee and cervical spine. Report of randomized, double blind, placebo controlled trials","volume":"21","author":"Trock","year":"1994"},{"issue":"Suppl 3","key":"b70-focus14742","series-title":"Neuro Oncol","first-page":"iii131","article-title":"NO-134. The effect of field strength on GBM response in patients treated with Novocure-TTF","volume":"15","author":"Turner","year":"2013"},{"key":"b71-focus14742","series-title":"World J Surg Oncol","first-page":"162","article-title":"The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF\u2122-100A system","volume":"12","author":"Turner","year":"2014"},{"key":"b72-focus14742","series-title":"NovoTTF-100A System - P100034","author":"US Food and Drug Administration"},{"key":"b73-focus14742","series-title":"Med Oncol","first-page":"338","article-title":"Delayed response and survival from NovoTTF-100A in recurrent GBM","volume":"30","author":"Villano","year":"2013"},{"key":"b74-focus14742","series-title":"J Clin Oncol","first-page":"4722","article-title":"Bevacizumab plus irinotecan in recurrent glioblastoma multiforme","volume":"25","author":"Vredenburgh","year":"2007"},{"key":"b75-focus14742","series-title":"Semin Oncol 41 Suppl","first-page":"S14","article-title":"Response patterns of recurrent glioblastomas treated with tumor treating fields (TTFields)","volume":"6","author":"Vymazal","year":"2014"},{"key":"b76-focus14742","series-title":"J Neurosurg","first-page":"333","article-title":"Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial","volume":"49","author":"Walker","year":"1978"},{"issue":"Suppl 3","key":"b77-focus14742","series-title":"Neuro Oncol","first-page":"iii84","article-title":"MR-036. A phase II randomized study of TTFields therapy versus supportive care in non-small cell lung cancer (NSCLC) patients with 1\u20133 brain metastases (BM) following stereotactic radio-surgery (SRS)","volume":"15","author":"Weinberg","year":"2013"},{"issue":"Suppl 3","key":"b78-focus14742","series-title":"Neuro Oncol","first-page":"iii241","article-title":"TM-028. Electric fields for the treatment of glioblastomas: a modeling study","volume":"15","author":"Wenger","year":"2013"},{"issue":"Suppl 3","key":"b79-focus14742","series-title":"Neuro Oncol","first-page":"iii134","article-title":"NO-146. Objective response in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure","volume":"15","author":"Wong","year":"2013"},{"issue":"Suppl 3","key":"b80-focus14742","series-title":"Neuro Oncol","first-page":"iii87","article-title":"OT-09. Updated survival data of the phase III clinical trial of NovoTTF-100A versus best standard chemotherapy for recurrent glioblastoma","volume":"13","author":"Wong","year":"2011"},{"key":"b81-focus14742","series-title":"J Am Soc Nephrol","first-page":"1381","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010"},{"key":"b82-focus14742","series-title":"J Neurophysiol","first-page":"2446","article-title":"Low-intensity electric fields induce two distinct response components in neocortical neuronal populations","volume":"112","author":"Xu","year":"2014"},{"key":"b83-focus14742","series-title":"J Clin Oncol","first-page":"2762","article-title":"Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse","volume":"17","author":"Yung","year":"1999"},{"key":"b84-focus14742","series-title":"Semin Cell Dev Biol","first-page":"674","article-title":"Electrical fields in wound healing\u2014an overriding signal that directs cell migration","volume":"20","author":"Zhao","year":"2009"},{"key":"b85-focus14742","series-title":"Proc Natl Acad Sci U S A","first-page":"4942","article-title":"A small, physiological electric field orients cell division","volume":"96","author":"Zhao","year":"1999"},{"key":"b86-focus14742","series-title":"Textbook of Stereotactic and Functional Neurosurgery","first-page":"1325","article-title":"Impedance recording in functional neurosurgery","volume":"1","author":"Zrinzo","year":"2009"},{"key":"b1-focus14742","series-title":"Stem Cell Rev","first-page":"585","article-title":"The influence of electric fields on hippocampal neural progenitor cells","volume":"6","author":"Ariza","year":"2010"},{"key":"b2-focus14742","series-title":"J Korean Med Sci","first-page":"980","article-title":"Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea","volume":"29","author":"Bae","year":"2014"},{"issue":"124","key":"b3-focus14742","series-title":"Clin Orthop Relat Res","first-page":"128","article-title":"A non-operative salvage of surgically-resistant pseudarthroses and non-unions by pulsing electromagnetic fields. A preliminary report","author":"Bassett","year":"1977"},{"key":"b4-focus14742","series-title":"Nature","first-page":"608","article-title":"Influencing intramolecular motion with an alternating electric field","volume":"406","author":"Bermudez","year":"2000"},{"key":"b5-focus14742","series-title":"J Neuropathol Exp Neurol","first-page":"201","article-title":"Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas","volume":"40","author":"Bigner","year":"1981"},{"key":"b6-focus14742","series-title":"Lancet","first-page":"1008","article-title":"Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas","volume":"345","author":"Brem","year":"1995"},{"key":"b7-focus14742","series-title":"Cancer","first-page":"1617","article-title":"Patient age, histologic features, and length of survival in patients with glioblastoma multiforme","volume":"59","author":"Burger","year":"1987"},{"key":"b8-focus14742","series-title":"J Int Med Res","first-page":"85","article-title":"Growth inhibition of malignant melanoma by intermediate frequency alternating electric fields, and the underlying mechanisms","volume":"40","author":"Chen","year":"2012"},{"key":"b9-focus14742","series-title":"Cancer","first-page":"2163","article-title":"Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries","volume":"118","author":"Darefsky","year":"2012"},{"key":"b10-focus14742","series-title":"Br J Neurosurg","first-page":"459","article-title":"The sequential use of carmustine wafers (Gliadel\u00ae) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review","volume":"25","author":"Dixit","year":"2011"},{"key":"b11-focus14742","series-title":"Case Rep Neurol","first-page":"109","article-title":"Resolution of cystic enhancement to add-on tumor treating electric fields for recurrent glioblastoma after incomplete response to bevacizumab","volume":"6","author":"Elzinga","year":"2014"},{"key":"b12-focus14742","series-title":"Cell Death Differ","first-page":"1238","article-title":"Chemotherapy resistance of glioblastoma stem cells","volume":"13","author":"Eramo","year":"2006"},{"issue":"Suppl 3","key":"b13-focus14742","series-title":"Neuro Oncol","first-page":"iii76","article-title":"MR-008. Phase III trial of tumor treating fields (TTFields) together with temozolomide (TMZ) compared to temozolomide alone in patients with newly diagnosed glioblastoma (GBM)","volume":"15","author":"Farber","year":"2013"},{"key":"b14-focus14742","series-title":"Expert Rev Neurother","first-page":"895","article-title":"NovoTTF-100A: a new treatment modality for recurrent glioblastoma","volume":"12","author":"Fonkem","year":"2012"},{"key":"b15-focus14742","series-title":"J Clin Oncol","first-page":"4733","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009"},{"key":"b16-focus14742","series-title":"Proc Natl Acad Sci U S A","first-page":"14142","article-title":"Electronic detection of DNA by its intrinsic molecular charge","volume":"99","author":"Fritz","year":"2002"},{"key":"b17-focus14742","series-title":"Electrophoresis","first-page":"1973","article-title":"Particle separation by dielectrophoresis","volume":"23","author":"Gascoyne","year":"2002"},{"issue":"Suppl 3","key":"b18-focus14742","series-title":"Neuro Oncol","first-page":"iii43","article-title":"ET-029. Overcoming cell size escape from tumor treating fields using a varying frequency treatment paradigm in-vitro","volume":"15","author":"Giladi","year":"2013"},{"issue":"Suppl 3","key":"b19-focus14742","series-title":"Neuro Oncol","first-page":"iii43","article-title":"ET-028. Alternating electric fields (TT-Fields) inhibit DNA damage repair response in cancer cell lines","volume":"15","author":"Giladi","year":"2013"},{"issue":"Suppl 3","key":"b20-focus14742","series-title":"Neuro Oncol","first-page":"iii86","article-title":"MP-005. Meta-analysis of cancer cell line genomes based on their response to alternating electric fields (TTFields)","volume":"15","author":"Giladi","year":"2013"},{"key":"b21-focus14742","series-title":"Angew Chem Int Ed Engl","first-page":"3022","article-title":"Why are proteins charged? Networks of charge-charge interactions in proteins measured by charge ladders and capillary electrophoresis","volume":"45","author":"Gitlin","year":"2006"},{"key":"b22-focus14742","series-title":"Ann Biomed Eng","first-page":"1759","article-title":"Electrically mediated neuronal guidance with applied alternating current electric fields","volume":"39","author":"Graves","year":"2011"},{"key":"b23-focus14742","series-title":"Oncology","first-page":"27","article-title":"Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis","volume":"79","author":"Hapani","year":"2010"},{"key":"b24-focus14742","series-title":"Biomed Microdevices","first-page":"657","article-title":"Electrical field manipulation of cancer cell behavior monitored by whole cell biosensing device","volume":"15","author":"Hondroulis","year":"2013"},{"key":"b25-focus14742","series-title":"J Neurooncol","first-page":"359","article-title":"Glioblastoma survival in the United States before and during the temozolomide era","volume":"107","author":"Johnson","year":"2012"},{"issue":"Suppl 3","key":"b26-focus14742","series-title":"Neuro Oncol","first-page":"iii114","article-title":"NO-065. Tumor treating fields (TTFields) in recurrent GBM. An updated subgroup analysis of the phase III data","volume":"15","author":"Kanner","year":"2013"},{"key":"b27-focus14742","series-title":"Semin Oncol 41 Suppl","first-page":"S25","article-title":"Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A\u2122 system versus best physician's choice chemotherapy","volume":"6","author":"Kanner","year":"2014"},{"key":"b28-focus14742","series-title":"Proc Natl Acad Sci U S A","first-page":"10152","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","volume":"104","author":"Kirson","year":"2007"},{"key":"b29-focus14742","series-title":"Cancer Res","first-page":"3288","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004"},{"key":"b30-focus14742","series-title":"BMC Med Phys","first-page":"1","article-title":"Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields)","volume":"9","author":"Kirson","year":"2009"},{"issue":"Suppl 4","key":"b31-focus14742","series-title":"Neuro Oncol","first-page":"iv48","article-title":"NO-54. Modeling tumor growth kinetics and its implications for TTFields treatment planning","volume":"12","author":"Kirson","year":"2010"},{"key":"b32-focus14742","series-title":"J BUON","first-page":"547","article-title":"Temozolomide-related infections: review of the literature","volume":"16","author":"Kizilarslanoglu","year":"2011"},{"key":"b33-focus14742","series-title":"J Clin Oncol","first-page":"740","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009"},{"key":"b34-focus14742","series-title":"Cancer","first-page":"649","article-title":"Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group","volume":"47","author":"Kristiansen","year":"1981"},{"issue":"Suppl 4","key":"b35-focus14742","series-title":"Semin Oncol","first-page":"S1","article-title":"Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma","volume":"41","author":"Lacouture","year":"2014"},{"key":"b36-focus14742","series-title":"J Neurosurg","first-page":"467","article-title":"Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project","volume":"99","author":"Laws","year":"2003"},{"issue":"Suppl 3","key":"b37-focus14742","series-title":"Neuro Oncol","first-page":"iii66","article-title":"IR-022. Disruption of cell division within anaphase by tumor treating electric fields (TTFields) leads to immunogenic cell death","volume":"15","author":"Lee","year":"2013"},{"key":"b38-focus14742","series-title":"Acta Neuropathol","first-page":"97","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007"},{"key":"b39-focus14742","series-title":"Biotechnol Prog","first-page":"664","article-title":"Alternating current electric field effects on neural stem cell viability and differentiation","volume":"26","author":"Matos","year":"2010"},{"key":"b40-focus14742","series-title":"J Neurosurg","first-page":"583","article-title":"Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme","volume":"110","author":"McGirt","year":"2009"},{"key":"b41-focus14742","series-title":"Annu Rev Cell Dev Biol","first-page":"193","article-title":"Chromosome-microtubule interactions during mitosis","volume":"18","author":"McIntosh","year":"2002"},{"key":"b42-focus14742","series-title":"Phys Med Biol","first-page":"4137","article-title":"Predicting the electric field distribution in the brain for the treatment of glioblastoma","volume":"59","author":"Miranda","year":"2014"},{"key":"b43-focus14742","series-title":"Semin Oncol 41 Suppl","first-page":"S4","article-title":"Clinical practice experience with NovoTTF-100A\u2122 system for glioblastoma: the Patient Registry Dataset (PRiDe)","volume":"6","author":"Mrugala","year":"2014"},{"issue":"Suppl 2","key":"b44-focus14742","series-title":"Neuro Oncol","first-page":"ii101","article-title":"P17.60. Novo-TTF 100A system used successfully in a patient with a ventriculo-peritoneal shunt","volume":"16","author":"Mrugala","year":"2014"},{"key":"b45-focus14742","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Central nervous system cancers. Version 2.2014","author":"National Comprehensive Cancer Network","year":"2014"},{"key":"b46-focus14742","series-title":"J Biomed Mater Res A","first-page":"2554","article-title":"Electric field stimulation through a biodegradable polypyrrole-co-polycaprolactone substrate enhances neural cell growth","volume":"102","author":"Nguyen","year":"2014"},{"key":"b47-focus14742","series-title":"Neurology","first-page":"779","article-title":"Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence","volume":"70","author":"Norden","year":"2008"},{"key":"b48-focus14742","series-title":"Biochem Biophys Res Commun","first-page":"351","article-title":"Nanosecond pulsed electric fields cause melanomas to self-destruct","volume":"343","author":"Nuccitelli","year":"2006"},{"key":"b49-focus14742","series-title":"Neuro Oncol","first-page":"iv1","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011","volume":"16 Suppl 4","author":"Ostrom","year":"2014"},{"key":"b50-focus14742","series-title":"J Neurosci Res","first-page":"1522","article-title":"Neuronal responses to an asymmetrical alternating current field can mimic those produced by an imposed direct current field in vitro","volume":"90","author":"Pan","year":"2012"},{"key":"b51-focus14742","series-title":"J Cell Physiol","first-page":"602","article-title":"5'-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells","volume":"228","author":"Quezada","year":"2013"},{"key":"b52-focus14742","series-title":"J Neurosci","first-page":"3030","article-title":"Spike timing amplifies the effect of electric fields on neurons: implications for endogenous field effects","volume":"27","author":"Radman","year":"2007"},{"issue":"Suppl 4","key":"b53-focus14742","series-title":"Neuro Oncol","first-page":"iv48","article-title":"NO-55. Subgroup and quality of life analyses of the phase III clinical trial of NovoTTF-100A versus best standard chemotherapy for recurrent glioblastoma","volume":"12","author":"Ram","year":"2010"},{"issue":"Suppl 3","key":"b54-focus14742","series-title":"Neuro Oncol","first-page":"iii52","article-title":"NO-50. Comparing the effect of NovoTTF to bevacizumab in recurrent GBM: a post-hoc sub-analysis of the phase III trial data","volume":"13","author":"Ram","year":"2011"},{"key":"b55-focus14742","series-title":"Front Hum Neurosci","first-page":"687","article-title":"Effects of weak transcranial alternating current stimulation on brain activity\u2014 a review of known mechanisms from animal studies","volume":"7","author":"Reato","year":"2013"},{"key":"b56-focus14742","series-title":"World J Surg Oncol","first-page":"220","article-title":"Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields","volume":"10","author":"Rulseh","year":"2012"},{"key":"b57-focus14742","series-title":"J Neurosurg Sci","first-page":"1","article-title":"Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis","volume":"55","author":"Salvati","year":"2011"},{"key":"b58-focus14742","series-title":"Exp Cell Res","first-page":"380","article-title":"Redox control of angiogenic factors and CD31-positive vessel-like structures in mouse embryonic stem cells after direct current electrical field stimulation","volume":"304","author":"Sauer","year":"2005"},{"key":"b59-focus14742","series-title":"Oncogene","first-page":"1385","article-title":"Comparative molecular genetic profiles of anaplastic astrocytomas\/glioblastomas multiforme and their subsequent recurrences","volume":"18","author":"Saxena","year":"1999"},{"issue":"Suppl 3","key":"b60-focus14742","series-title":"Neuro Oncol","first-page":"iii99","article-title":"NO-006. Radiographic response of an incidental meningioma in a patient with glioblastoma on NovoTTF therapy","volume":"15","author":"Schaff","year":"2013"},{"key":"b61-focus14742","series-title":"CA Cancer J Clin","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014"},{"key":"b62-focus14742","series-title":"J Cell Biochem","first-page":"404","article-title":"Prospects on clinical applications of electrical stimulation for nerve regeneration","volume":"51","author":"Sisken","year":"1993"},{"key":"b63-focus14742","series-title":"Lancet Oncol","first-page":"459","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009"},{"key":"b64-focus14742","series-title":"N Engl J Med","first-page":"987","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005"},{"key":"b65-focus14742","series-title":"Eur J Cancer","first-page":"2192","article-title":"NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012"},{"key":"b66-focus14742","series-title":"BioDrugs","first-page":"159","article-title":"Bevacizumab-induced hypertension: pathogenesis and management","volume":"25","author":"Syrigos","year":"2011"},{"key":"b67-focus14742","series-title":"Bioelectrochemistry","first-page":"257","article-title":"Electroporation and alternating current cause membrane permeation of photodynamic cytotoxins yielding necrosis and apoptosis of cancer cells","volume":"79","author":"Traitcheva","year":"2010"},{"key":"b68-focus14742","series-title":"Physiol Meas","first-page":"13","article-title":"Computational modelling of blood-flow-induced changes in blood electrical conductivity and its contribution to the impedance cardiogram","volume":"31","author":"Trakic","year":"2010"},{"key":"b69-focus14742","series-title":"J Rheumatol","first-page":"1903","article-title":"The effect of pulsed electromagnetic fields in the treatment of osteoarthritis of the knee and cervical spine. Report of randomized, double blind, placebo controlled trials","volume":"21","author":"Trock","year":"1994"},{"issue":"Suppl 3","key":"b70-focus14742","series-title":"Neuro Oncol","first-page":"iii131","article-title":"NO-134. The effect of field strength on GBM response in patients treated with Novocure-TTF","volume":"15","author":"Turner","year":"2013"},{"key":"b71-focus14742","series-title":"World J Surg Oncol","first-page":"162","article-title":"The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF\u2122-100A system","volume":"12","author":"Turner","year":"2014"},{"key":"b72-focus14742","series-title":"NovoTTF-100A System - P100034","author":"US Food and Drug Administration"},{"key":"b73-focus14742","series-title":"Med Oncol","first-page":"338","article-title":"Delayed response and survival from NovoTTF-100A in recurrent GBM","volume":"30","author":"Villano","year":"2013"},{"key":"b74-focus14742","series-title":"J Clin Oncol","first-page":"4722","article-title":"Bevacizumab plus irinotecan in recurrent glioblastoma multiforme","volume":"25","author":"Vredenburgh","year":"2007"},{"key":"b75-focus14742","series-title":"Semin Oncol 41 Suppl","first-page":"S14","article-title":"Response patterns of recurrent glioblastomas treated with tumor treating fields (TTFields)","volume":"6","author":"Vymazal","year":"2014"},{"key":"b76-focus14742","series-title":"J Neurosurg","first-page":"333","article-title":"Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial","volume":"49","author":"Walker","year":"1978"},{"issue":"Suppl 3","key":"b77-focus14742","series-title":"Neuro Oncol","first-page":"iii84","article-title":"MR-036. A phase II randomized study of TTFields therapy versus supportive care in non-small cell lung cancer (NSCLC) patients with 1\u20133 brain metastases (BM) following stereotactic radio-surgery (SRS)","volume":"15","author":"Weinberg","year":"2013"},{"issue":"Suppl 3","key":"b78-focus14742","series-title":"Neuro Oncol","first-page":"iii241","article-title":"TM-028. Electric fields for the treatment of glioblastomas: a modeling study","volume":"15","author":"Wenger","year":"2013"},{"issue":"Suppl 3","key":"b79-focus14742","series-title":"Neuro Oncol","first-page":"iii134","article-title":"NO-146. Objective response in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure","volume":"15","author":"Wong","year":"2013"},{"issue":"Suppl 3","key":"b80-focus14742","series-title":"Neuro Oncol","first-page":"iii87","article-title":"OT-09. Updated survival data of the phase III clinical trial of NovoTTF-100A versus best standard chemotherapy for recurrent glioblastoma","volume":"13","author":"Wong","year":"2011"},{"key":"b81-focus14742","series-title":"J Am Soc Nephrol","first-page":"1381","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010"},{"key":"b82-focus14742","series-title":"J Neurophysiol","first-page":"2446","article-title":"Low-intensity electric fields induce two distinct response components in neocortical neuronal populations","volume":"112","author":"Xu","year":"2014"},{"key":"b83-focus14742","series-title":"J Clin Oncol","first-page":"2762","article-title":"Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse","volume":"17","author":"Yung","year":"1999"},{"key":"b84-focus14742","series-title":"Semin Cell Dev Biol","first-page":"674","article-title":"Electrical fields in wound healing\u2014an overriding signal that directs cell migration","volume":"20","author":"Zhao","year":"2009"},{"key":"b85-focus14742","series-title":"Proc Natl Acad Sci U S A","first-page":"4942","article-title":"A small, physiological electric field orients cell division","volume":"96","author":"Zhao","year":"1999"},{"key":"b86-focus14742","series-title":"Textbook of Stereotactic and Functional Neurosurgery","first-page":"1325","article-title":"Impedance recording in functional neurosurgery","volume":"1","author":"Zrinzo","year":"2009"}],"container-title":["Neurosurgical Focus"],"original-title":[],"link":[{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/38\/3\/article-pE14.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/38\/3\/article-pE14.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/thejns.org\/downloadpdf\/journals\/neurosurg-focus\/38\/3\/article-pE14.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T08:48:25Z","timestamp":1779526105000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejns.org\/view\/journals\/neurosurg-focus\/38\/3\/article-pE14.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":172,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3171\/2015.1.focus14742","relation":{},"ISSN":["1092-0684"],"issn-type":[{"value":"1092-0684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}